1. Home
  2. NRSN vs IHT Comparison

NRSN vs IHT Comparison

Compare NRSN & IHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • IHT
  • Stock Information
  • Founded
  • NRSN 2017
  • IHT 1971
  • Country
  • NRSN Israel
  • IHT United States
  • Employees
  • NRSN N/A
  • IHT N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • IHT Investment Bankers/Brokers/Service
  • Sector
  • NRSN Health Care
  • IHT Finance
  • Exchange
  • NRSN Nasdaq
  • IHT Nasdaq
  • Market Cap
  • NRSN 24.7M
  • IHT 15.6M
  • IPO Year
  • NRSN 2021
  • IHT N/A
  • Fundamental
  • Price
  • NRSN $1.10
  • IHT $1.94
  • Analyst Decision
  • NRSN
  • IHT
  • Analyst Count
  • NRSN 0
  • IHT 0
  • Target Price
  • NRSN N/A
  • IHT N/A
  • AVG Volume (30 Days)
  • NRSN 150.1K
  • IHT 2.9K
  • Earning Date
  • NRSN 11-26-2024
  • IHT 12-05-2024
  • Dividend Yield
  • NRSN N/A
  • IHT 1.01%
  • EPS Growth
  • NRSN N/A
  • IHT N/A
  • EPS
  • NRSN N/A
  • IHT N/A
  • Revenue
  • NRSN N/A
  • IHT $7,691,676.00
  • Revenue This Year
  • NRSN N/A
  • IHT N/A
  • Revenue Next Year
  • NRSN N/A
  • IHT N/A
  • P/E Ratio
  • NRSN N/A
  • IHT N/A
  • Revenue Growth
  • NRSN N/A
  • IHT 6.27
  • 52 Week Low
  • NRSN $0.40
  • IHT $1.11
  • 52 Week High
  • NRSN $2.33
  • IHT $2.25
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 46.61
  • IHT 53.32
  • Support Level
  • NRSN $0.92
  • IHT $1.77
  • Resistance Level
  • NRSN $1.22
  • IHT $1.98
  • Average True Range (ATR)
  • NRSN 0.11
  • IHT 0.06
  • MACD
  • NRSN -0.04
  • IHT 0.01
  • Stochastic Oscillator
  • NRSN 40.00
  • IHT 81.33

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About IHT InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.

Share on Social Networks: